Association Study of Selected Genetic Polymorphisms and Occurrence of Venous Thromboembolism in Patients With Multiple Myeloma Who Were Treated With Thalidomide
| Autor: | Roman Hájek, Petra Kaisarova, Tomas Pika, Martina Almáši, Miroslav Penka, Vladimir Maisnar, Sabina Ševčíková, Ludek Pour, Hana Šváchová, Ondrej Slaby, Jakub Radocha, Vlastimil Scudla |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male Risk Oncology Cancer Research Candidate gene medicine.medical_specialty Genotype Antineoplastic Agents Single-nucleotide polymorphism Polymorphism Single Nucleotide 03 medical and health sciences 0302 clinical medicine Gene Frequency Internal medicine Humans Medicine cardiovascular diseases Alleles Genetic Association Studies Multiple myeloma Aged Retrospective Studies 030304 developmental biology Aged 80 and over 0303 health sciences business.industry Retrospective cohort study Venous Thromboembolism Hematology Odds ratio Middle Aged Prognosis medicine.disease Thalidomide 3. Good health Surgery 030220 oncology & carcinogenesis Cohort Female Multiple Myeloma business medicine.drug |
| Zdroj: | Clinical Lymphoma Myeloma and Leukemia. 11:414-420 |
| ISSN: | 2152-2650 |
| Popis: | Introduction/Background Venous thromboembolism (VTE), with the subsequent risk of pulmonary embolism, is a common adverse effect of thalidomide treatment in patients with multiple myeloma (MM). In our retrospective study, we analyzed candidate single-nucleotide polymorphisms (SNP), CINP (rs7011), CETP (rs289747), ALDH1A1 (rs610529), CDKN1A (rs3829963), GAN (rs2608555), vascular endothelial growth factor (rs699947), and ALDH1A1 (rs168351), previously identified in a large association study based on the hypothesis-driven candidate gene approach nominated by the International Myeloma Foundation “Bank On A Cure” (3404 SNPs). In that study, the researchers built a classification tree that enables prediction of individual risk of VTE in patients with MM. Patients and Methods Genotypes of these SNPs were determined in an independent cohort of 111 patients with MM through TaqMan real-time polymerase chain reaction (PCR) allelic discrimination and were used for prediction of individual VTE risk. Results The results of this study did not confirm the ability of this classification tree to predict VTE risk in patients with MM from the Czech Republic; of these patients, 21 (19%) developed high-grade VTE. However, in patients with VTE, we found higher frequency of the AC genotype in the CDKN1A gene (42.9% vs. 16.7%; odds ratio 3.64) in comparison with the CC genotype (P = .015). SNPs of other genes as well as age and sex of the patients had no statistically significant influence on the risk of VTE. Conclusion Further studies are needed to confirm the initial analysis that provided predictive information of genetic variations in patients with myeloma that may influence risk of VTE. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect